JP2007070263A - Composition for preventing diabetes mellitus - Google Patents
Composition for preventing diabetes mellitus Download PDFInfo
- Publication number
- JP2007070263A JP2007070263A JP2005257166A JP2005257166A JP2007070263A JP 2007070263 A JP2007070263 A JP 2007070263A JP 2005257166 A JP2005257166 A JP 2005257166A JP 2005257166 A JP2005257166 A JP 2005257166A JP 2007070263 A JP2007070263 A JP 2007070263A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- buckwheat
- diabetes
- extract
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 46
- 239000000284 extract Substances 0.000 claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 8
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 8
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 8
- 235000005493 rutin Nutrition 0.000 claims abstract description 8
- 229960004555 rutoside Drugs 0.000 claims abstract description 8
- 241000219051 Fagopyrum Species 0.000 claims abstract 4
- 238000000605 extraction Methods 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 240000008620 Fagopyrum esculentum Species 0.000 description 42
- 241000700159 Rattus Species 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000020940 control diet Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000013353 coffee beverage Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- -1 gummi Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 244000248416 Fagopyrum cymosum Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- XUDNWQSXPROHLK-OACYRQNASA-N 2-phenyl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC=CC=2)OC2=CC=CC=C2C1=O XUDNWQSXPROHLK-OACYRQNASA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000004181 Eucalyptus cladocalyx Species 0.000 description 1
- 235000010852 Fagopyrum cymosum Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000208251 Gymnema Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000021539 instant coffee Nutrition 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、糖尿病予防用組成物に関するものである。 The present invention relates to a composition for preventing diabetes.
糖尿病には、インスリン依存型糖尿病(I型糖尿病)とインスリン非依存型糖尿病(II型糖尿病)の2タイプがあるが、全体の90%は後者のタイプである。
後者(II型糖尿病)は、過栄養によるインスリンの作用不足(例えば組織におけるインスリン感受性低下、膵臓のインスリン分泌不足等)による糖・脂質代謝の異常が原因といわれている。
インスリン非依存型糖尿病(II型糖尿病)は、薬物による治療より、まずは食事療法、運動療法でコントロールすることが基本とされるが、そのように自己管理がなされていても必ずしも代謝異常が是正されるとは限らず、薬に依存しがちである。
ところが、薬剤には、投与による副作用や使用量、使用制限に制限の問題がある。また、これらは単一化された物質の混合によるものがほとんどであるため、単一物質の副作用、さらには長期に亘る服用により起こる安全性の面からも問題になっている。
There are two types of diabetes, insulin-dependent diabetes (type I diabetes) and non-insulin-dependent diabetes (type II diabetes), of which 90% are of the latter type.
The latter (type II diabetes) is said to be caused by abnormal sugar / lipid metabolism due to insufficient insulin action due to overnutrition (eg, decreased insulin sensitivity in tissues, insufficient insulin secretion in pancreas, etc.).
Non-insulin-dependent diabetes mellitus (type II diabetes) is basically controlled by diet therapy and exercise therapy rather than drug treatment, but even if such self-management is carried out, metabolic abnormalities are not necessarily corrected. It is not always true, and it tends to depend on drugs.
However, there are problems with drugs in terms of side effects, dosages, and restrictions on use. Moreover, since these are mostly due to the mixture of the unified substances, there are problems from the side effects of the single substance and the safety caused by long-term use.
従来、このような糖質の代謝異常を是正する植物由来の物質としては、ギムネマ、グアバ、バナバ、桑などの葉から得られる抽出物が知られる。これらの植物由来の抽出物は、安全性の面から食品、医薬品等に応用しやすいため、有効成分等について研究が行われている。 Conventionally, extracts derived from leaves such as Gymnema, guava, banaba and mulberry are known as plant-derived substances that correct such metabolic abnormalities of carbohydrates. Since these plant-derived extracts are easy to apply to foods, pharmaceuticals and the like from the viewpoint of safety, research on active ingredients and the like has been conducted.
このような背景の下、本発明者らは、種々の植物由来の抽出物について、そばのエタノール抽出物に着目するに至った。
そして、各種の実験を行った結果、この抽出物に含まれるルチンが、血糖値を有効に降下させることを見出した。
本発明は、糖尿病の予防・緩和および肥満の防止にきわめて有効なそば由来の糖尿病予防用組成物およびそれらの製造方法を提供することを目的とする。
Under such a background, the present inventors came to pay attention to buckwheat ethanol extract for extracts derived from various plants.
As a result of various experiments, it was found that rutin contained in this extract effectively lowers the blood glucose level.
It is an object of the present invention to provide a composition for preventing diabetes derived from buckwheat that is extremely effective in preventing and / or alleviating diabetes and preventing obesity, and a method for producing them.
上記課題を解決するために、本発明の糖尿病予防用組成物は、ルチンを有効成分とすることを特徴とする。
また、本発明の糖尿病予防用組成物は、ソバ(蕎麦)の葉部、茎部、花部及び種子のうちの少なくとも一種を含む地上部の溶媒抽出物を含有することを特徴とする。
更に、前記溶媒抽出物の抽出溶媒が含水エタノールであることが好ましい。
In order to solve the above problems, the composition for preventing diabetes according to the present invention is characterized by containing rutin as an active ingredient.
In addition, the composition for preventing diabetes according to the present invention is characterized by containing an above-ground solvent extract containing at least one of leaves, stems, flowers and seeds of buckwheat (buckwheat).
Furthermore, it is preferable that the extraction solvent of the solvent extract is hydrous ethanol.
以下、本発明の実施の形態について、詳細に説明する。 Hereinafter, embodiments of the present invention will be described in detail.
本発明の糖尿病予防用組成物は、ルチンを有効成分とすることを特徴とする。ルチンとは、下記の化学式にて示されるフラボノール配糖体の一種である。 The composition for preventing diabetes of the present invention comprises rutin as an active ingredient. Rutin is a kind of flavonol glycoside represented by the following chemical formula.
上記ルチンを抽出する原料として、特に限定されないが、ミカン科のヘンルーダ(Ruta graveolens LINNE)、マメ科のエンジュ(Sophra japonica LINNE)の花蕾、及びタデ科のそば等から得ることができるが、タデ科のそばから得ることが好ましい。
ソバ(蕎麦)は、タデ科の一年草で、その種実は“そば粉”の原料として知られている。三角形の葉を互生し,葉柄基部に茎を取り囲むサヤ状の托葉をもつ。茎は片側にくぼみをもつ円筒形であり、茎の先端数節に、総状花序で多数の花をつける。
The raw material for extracting rutin is not particularly limited. It is preferable to obtain from soba.
Buckwheat (soba) is an annual plant of the Tedaceae family, and its seed is known as a raw material for “buckwheat flour”. Triangular leaves alternate with each other and have a Saya-shaped bamboo leaf surrounding the stem at the base of the petiole. The stem has a cylindrical shape with a depression on one side, and a large number of flowers are attached at the tip of the stem with a general inflorescence.
本発明の糖尿病予防用組成物を抽出するための原料としては、主に、ソバの葉部、茎部、花部、及び種子のうちの少なくとも一種含む地上部を用いる。即ち、葉部、茎部、花部、及び種子の混合物を使用してもよいし、葉部、茎部、花部及び種子のいずれかを単独で使用してもよい。また、根部等を混合したものを抽出原料として使用してもよい。これらのうち、葉部を含有するものが特に好ましい。ルチン等の有効成分の含有量をより高めることができるからである。 As a raw material for extracting the composition for preventing diabetes of the present invention, an above-ground part containing at least one of buckwheat leaf part, stem part, flower part and seed is mainly used. That is, a mixture of leaves, stems, flowers, and seeds may be used, or any of leaves, stems, flowers, and seeds may be used alone. Moreover, you may use what mixed the root part etc. as an extraction raw material. Of these, those containing leaves are particularly preferred. This is because the content of active ingredients such as rutin can be further increased.
ソバの品種は、作期に応じて夏ソバ、秋ソバあるいは両者の中間型などに分けられており、また、栽培種としては、本種:Fagopyrum esculentum Moenchの他、耐冷性のダッタンソバ:F.tataricum Gaertn.(ニガソバともいう。)、多年生のシャクチリソバ:F.cymosum Meisn.(シュッコンソバともいう。) などがある。
本発明の糖尿病予防用組成物を抽出するための原料としては、本種を用いるのが好ましいが、上記のいずれの品種であっても使用することができる。また、産地等も限定されない。
The buckwheat varieties are divided into summer buckwheat, autumn buckwheat, or an intermediate type between the two depending on the cropping season. tataricum Gaertn. (Also referred to as “Nigasoba”), perennial Shakuchirisoba: F. cymosum Meisn. (It is also referred to as Sukkon Soba.)
As a raw material for extracting the composition for preventing diabetes according to the present invention, this species is preferably used, but any of the above varieties can be used. Also, the production area is not limited.
ソバの葉部、茎部、花部、種子等の抽出原料は、生のままで使用することもできるが、好ましくは、乾燥物を使用する。乾燥方法としては、天日で行う方法の他、陰干し、風乾、熱風乾燥、冷凍乾燥など公知の方法で乾燥することができる。
また、抽出原料は、粉砕機等により数mm以下のサイズに裁断または粉砕した粉砕物を用いるとよい。このような粉砕物を使用することにより、有効成分が抽出されやすくなる。
Extract raw materials such as buckwheat leaf part, stem part, flower part, seed and the like can be used as they are, but a dry product is preferably used. As a drying method, it can be dried by a publicly known method such as shade drying, air drying, hot air drying, freeze drying and the like.
The extraction raw material may be a pulverized product cut or pulverized into a size of several mm or less by a pulverizer or the like. Use of such a pulverized product facilitates extraction of active ingredients.
本発明の糖尿病予防用組成物を抽出するための溶媒としては、水、メタノール、エタノール、イソプロピルアルコール、アセトン、1,3−ブチレングリコール、エチレングリコール、プロピレングリコール、グリセリン、酢酸エチル等の溶媒を使用するとよい。これらの溶媒を2種以上混合したものを用いることもできる。好ましくは、水または含水エタノールを抽出溶媒として用いると、有効成分が効率よく抽出される。特に、含水エタノールは、抽出の際に有効成分の活性を保ちやすく、抽出物の食品使用における安全面の上でも好ましい抽出溶媒である。 As a solvent for extracting the composition for preventing diabetes according to the present invention, a solvent such as water, methanol, ethanol, isopropyl alcohol, acetone, 1,3-butylene glycol, ethylene glycol, propylene glycol, glycerin, ethyl acetate or the like is used. Good. A mixture of two or more of these solvents can also be used. Preferably, when water or hydrous ethanol is used as the extraction solvent, the active ingredient is efficiently extracted. In particular, hydrous ethanol is an extraction solvent that is easy to maintain the activity of the active ingredient during extraction and is preferable from the viewpoint of safety of the extract in food use.
抽出溶媒として水を使用する場合には、抽出温度20〜100℃、好ましくは80〜100℃程度で行うとよい。これは、抽出温度が低すぎると、有効成分が抽出されにくいためである。抽出用の水の種類は、特に限定されず、水道水、蒸留水、ミネラル水、アルカリイオン水等を使用することができる。好ましくは、抽出溶媒として、深層水(海洋深層水)を使用するとよい。 When water is used as the extraction solvent, the extraction temperature is 20 to 100 ° C., preferably about 80 to 100 ° C. This is because if the extraction temperature is too low, it is difficult to extract active ingredients. The kind of water for extraction is not particularly limited, and tap water, distilled water, mineral water, alkaline ionized water and the like can be used. Preferably, deep water (deep ocean water) is used as the extraction solvent.
抽出溶媒として含水エタノールを使用する場合、エタノール濃度30〜90%(容量比)であることが好ましい。30%(容量比)程度よりも少ないか、90%(容量比)を超えると、有効成分の抽出量が低下しやすくなるからである。また、抽出温度は、20〜80℃、好ましくは50〜80℃程度で行うとよい。なお、含水エタノール抽出は、有効成分の含有率を向上させるため、種々の濃度で繰り返すとよい。 When hydrous ethanol is used as the extraction solvent, the ethanol concentration is preferably 30 to 90% (volume ratio). This is because if the amount is less than about 30% (volume ratio) or exceeds 90% (volume ratio), the extraction amount of the active ingredient tends to decrease. The extraction temperature is 20 to 80 ° C, preferably about 50 to 80 ° C. In addition, the water-containing ethanol extraction may be repeated at various concentrations in order to improve the content of the active ingredient.
本発明の糖尿病予防用組成物の抽出方法としては、連続抽出、浸漬抽出、向流抽出、超臨界抽出など任意の方法を採用することができ、室温ないし還流加熱下において任意の装置を使用することができる。 As a method for extracting the composition for preventing diabetes according to the present invention, any method such as continuous extraction, immersion extraction, countercurrent extraction, and supercritical extraction can be employed, and an arbitrary apparatus is used at room temperature or under reflux heating. be able to.
具体的な方法としては、抽出溶媒を満たした処理槽に抽出原料を投入し、攪拌しながら有効成分を溶出させる。例えば、抽出溶媒として水または含水エタノールを用いる場合には、抽出原料の5〜100倍量程度(重量比)の極性溶媒を使用し、30分〜2時間程度抽出を行う。溶媒中に有効成分を溶出させた後、ろ過して抽出残渣を除くことによって、抽出液を得る。その後、常法に従って抽出液に希釈、濃縮、乾燥、精製等の処理を施し、糖尿病予防用組成物とする。
なお、精製方法としては、例えば、活性炭処理、樹脂吸着処理、イオン交換樹脂、液−液向流分配等の方法が挙げられるが、食品等に添加する場合には大量に使用するものではないから、未精製のままで使用してもよい。
As a specific method, an extraction raw material is put into a treatment tank filled with an extraction solvent, and an active ingredient is eluted while stirring. For example, when water or water-containing ethanol is used as the extraction solvent, the extraction is performed for about 30 minutes to 2 hours using a polar solvent of about 5 to 100 times (weight ratio) of the extraction raw material. The active ingredient is eluted in the solvent, and then filtered to remove the extraction residue to obtain an extract. Thereafter, the extract is subjected to treatments such as dilution, concentration, drying and purification according to a conventional method to obtain a composition for preventing diabetes.
Examples of the purification method include activated carbon treatment, resin adsorption treatment, ion exchange resin, liquid-liquid countercurrent distribution, and the like, but they are not used in large quantities when added to foods. It may be used unpurified.
本発明の糖尿病予防用組成物は、飲食品に含有させることができる。例えば、菓子類(ガム、キャンディー、キャラメル、チョコレート、クッキー、スナック、ゼリー、グミ、錠菓等)、麺類(そば、うどん、ラーメン等)、乳製品(ミルク、アイスクリーム、ヨーグルト等)、調味料(味噌、醤油等)、スープ類、飲料(ジュース、コーヒー、紅茶、茶、炭酸飲料、スポーツ飲料等)をはじめとする一般食品や、健康食品(錠剤、カプセル等)、栄養補助食品(栄養ドリンク等)等が挙げられる。 The composition for diabetes prevention of this invention can be contained in food-drinks. For example, confectionery (gum, candy, caramel, chocolate, cookies, snacks, jelly, gummi, tablet confectionery, etc.), noodles (soba, udon, ramen, etc.), dairy products (milk, ice cream, yogurt, etc.), seasonings (Miso, soy sauce, etc.), soups, beverages (juice, coffee, tea, tea, carbonated drinks, sports drinks, etc.), general foods, health foods (tablets, capsules, etc.), nutritional supplements (nutrient drinks) Etc.).
インスタント食品に本発明の糖尿病予防用組成物を添加してもよい。例えば、糖尿病予防用組成物を粉末セルロースとともにスプレードライまたは凍結乾燥したものを、粉末、顆粒、打錠または溶液にすることで容易に飲食品に含有させることができる。
また、本発明の糖尿病予防用組成物を、例えば、油脂、エタノール、プロピレングリコール、グリセリンあるいはこれらの混合物に溶解して液状にし、飲料に添加するか、固形食品に添加することが可能である。さらに、必要に応じてアラビアガム、デキストリン等のバインダーと混合して粉末状あるいは顆粒状にし、飲料に添加するか固形食品に添加することも可能である。
You may add the composition for diabetes prevention of this invention to an instant foodstuff. For example, a composition obtained by spray-drying or freeze-drying a composition for preventing diabetes together with powdered cellulose can be easily contained in a food or drink by making it into a powder, granule, tablet or solution.
In addition, the composition for preventing diabetes according to the present invention can be dissolved in, for example, fats and oils, ethanol, propylene glycol, glycerin or a mixture thereof to be liquefied and added to beverages or added to solid foods. Further, if necessary, it can be mixed with a binder such as gum arabic or dextrin to form a powder or granule and added to a beverage or a solid food.
本発明の糖尿病予防用組成物を飲食品に適用する場合の添加量としては、病気予防や健康維持が目的であるので、飲食品に対して糖尿病予防用組成物の含量が合計1〜20重量%であるのが好ましい。 When the composition for preventing diabetes according to the present invention is applied to foods and drinks, since the purpose is to prevent diseases and maintain health, the content of the composition for preventing diabetes is 1 to 20 weights in total for foods and drinks. % Is preferred.
本発明の糖尿病予防用組成物は、医薬品の有効成分として使用してもよい。本発明の「医薬品」は、病気の予防や治療に用いるものであれば、医薬品および医薬部外品のいずれであってもよい。
医薬品としての糖尿病予防用組成物の投与方法は、経口投与することが好ましい。一般的には錠剤、丸剤、軟・硬カプセル剤、細粒剤、散剤、顆粒剤、液剤等の形態とすることができる。
また、本発明の医薬品を非経口投与してもよい。非経口剤として投与する場合、溶液の状態、または分散剤、懸濁剤、安定剤などを添加した状態で、注射剤、坐剤などの形態とすることができる。
You may use the composition for diabetes prevention of this invention as an active ingredient of a pharmaceutical. The “medicament” of the present invention may be either a medicinal product or a quasi-drug as long as it is used for prevention or treatment of diseases.
The method for administering the composition for preventing diabetes as a pharmaceutical is preferably administered orally. Generally, it can be in the form of tablets, pills, soft / hard capsules, fine granules, powders, granules, liquids and the like.
Moreover, you may administer the pharmaceutical of this invention parenterally. When administered as a parenteral preparation, it can be in the form of an injection, a suppository, or the like in the form of a solution or with a dispersion, suspension, stabilizer or the like added.
糖尿病予防用組成物の投与量は、年齢、体重、症状、治療効果、投与方法、処理時間等により異なるが、通常成人一人あたり、1回に1mg〜1000mgの範囲で、1日1回から数回経口投与されるか、または、1回に100μg〜100mgの範囲で、1日1回から数回非経口投与される。
なお、投与量は種々の条件で異なるので、前記投与量より少ない量で十分な場合もあるし、また、範囲を超えて投与する必要のある場合もある。
The dosage of the composition for preventing diabetes varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but usually ranges from 1 mg to 1000 mg per adult and once to several times a day. It is administered orally once, or parenterally once to several times a day in the range of 100 μg to 100 mg at a time.
In addition, since the dose varies depending on various conditions, a dose smaller than the above dose may be sufficient, or it may be necessary to administer beyond the range.
以下、本発明を具体化した実施例について詳細に説明する。
ソバの葉部と茎部とからなる乾燥物(花部もわずかに含まれる。)を入手し、粉砕機により粉砕した。この粉砕物5kgを抽出用の原料として使用した。
原料粉砕物にエタノール濃度90%(容量比)の含水エタノールを約10倍量加え、2時間加熱還流して抽出を行った。その後、含水エタノール抽出液をろ過して残渣を除き、ろ液の溶媒を除去してソバ抽出物(ソバエキス400g)を得た。
Hereinafter, embodiments embodying the present invention will be described in detail.
A dried product comprising a buckwheat leaf portion and a stem portion (including a small amount of flower portion) was obtained and pulverized by a pulverizer. 5 kg of this pulverized product was used as a raw material for extraction.
About 10 times the amount of hydrous ethanol having an ethanol concentration of 90% (volume ratio) was added to the pulverized raw material, and extraction was performed by heating under reflux for 2 hours. Thereafter, the aqueous ethanol extract was filtered to remove the residue, and the solvent of the filtrate was removed to obtain a buckwheat extract (buckwheat extract 400 g).
製造されたソバエキスの機能性を検討するために以下の動物実験を行った。 In order to examine the functionality of the produced buckwheat extract, the following animal experiment was conducted.
上記方法により製造されたソバエキスを含む飼料をラットに摂取させた。比較として、ソバの葉エキスを含まない飼料をラットに摂取させた。 Rats were fed a diet containing buckwheat extract produced by the above method. For comparison, rats were fed a diet that did not contain buckwheat leaf extract.
一ヶ月齢の2型糖尿病を遺伝的に自然発症する雄性のOtsuka Long-Evans Tokushima Fatty ラット(以下OLETFラットという)と、その対照モデル動物で糖尿病を発症しない雄性のLong-Evans Tokushima Otsukaラット(以下LETOラットという)を用いた。ラットは、室温22±1℃、室温55±5%、8:00〜20:00点灯のライトサイクルの動物飼育室で飼育した。
Male Otsuka Long-Evans Tokushima Fatty rats (hereinafter referred to as OLETF rats) that genetically spontaneously develop one-month-
最初の3ヶ月間はLETOおよびOLETFラットにMF固形飼料を与えて予備飼育を行った。OLETFラットは通常5ヶ月齢から8ヶ月齢までに2型糖尿病を発症することから、発症の可能性のある1ヶ月前の4ヶ月齢からLETOラットと共に試験食の摂食を開始した。
During the first 3 months, MF chow diets were given to LETO and OLETF rats for preliminary breeding. Since OLETF rats usually develop
4ヶ月齢の時に6時間絶食(9:00〜15:00)後、尾静脈より採血して血糖値を測定し、体重と血糖値が等しくなるように1群6匹ずつに群分けし、以下の試験食を5ヶ月間自由摂食させた。 After 4 hours of fasting for 6 hours (9:00 〜 15:00), blood was collected from the tail vein, blood glucose level was measured, and grouped into 6 animals per group so that body weight and blood glucose level were equal Then, the following test meals were fed freely for 5 months.
試験食は、AIN-76に基づいた純化食をコントロール食とし、LETOラットとOLETFラットのコントロール群に摂食させた。飼料の重量組成(g/kg)は、カゼイン200、コーン油100、ミネラル混合(AIN-76-MX)35、ビタミン混合(AIN-76-VX)10、セルロース50、重酒石酸コリン2、DL-メチオニン3、コーンスターチ150およびショ糖450とした。ソバの葉エキス添加食には、ソバエキスを飼料総重量の5%添加し、その添加量分のショ糖量を減じた。飼育期間中、摂食量は毎日、体重および摂水量は1日おきに測定した。
The test diet was a purified diet based on AIN-76, which was fed to a control group of LETO and OLETF rats. Weight composition (g / kg) of feed is 200 casein, 100 corn oil, 35 mineral mixture (AIN-76-MX), 35 vitamin mixture (AIN-76-VX), 50 cellulose, 2 choline bitartrate, DL-
試験食投与開始1、2、3、4および5ヶ月後に、血糖試験測定メディセーフチップ(テルモ、東京)を用い、6時間絶食後尾静脈より採血して血糖値を測定した。試験食を摂取した5ヶ月間のラット血糖値の変化を図1に示す。 1, 2, 3, 4 and 5 months after the start of test meal administration, blood glucose was measured using a Medisafe chip (Terumo, Tokyo) and blood was collected from the tail vein after fasting for 6 hours. FIG. 1 shows the change in blood glucose level in rats over 5 months after taking the test meal.
図1に示すように、コントロール食を摂取した糖尿病を発症しないLETOラットの血糖値は、飼育期間を通じて低値であった。一方、コントロール食を摂取した糖尿病を発症するOLETFラットの血糖値は、経時的に上昇し、糖尿病を発症したとみなされた。ソバエキスを摂取したOLETFラットの血糖値は飼育期間中あまり上昇せず、コントロール食を摂取したOLETFラットより著しく低い値で推移した。このことから、ソバエキスは優れた血糖上昇抑制効果を有することが明らかとなった。 As shown in FIG. 1, the blood glucose level of LETO rats that did not develop diabetes who took the control diet was low throughout the breeding period. On the other hand, the blood glucose level of OLETF rats that developed diabetes that took the control diet increased over time, and was considered to have developed diabetes. The blood glucose level of OLETF rats fed with buckwheat extract did not rise significantly during the breeding period, and remained at a significantly lower level than that of OLETF rats fed control food. From this, it was revealed that buckwheat extract has an excellent inhibitory effect on the increase in blood sugar.
コントロール食摂取OLETFラットの5ヶ月後の血清インスリン濃度は糖尿病発症により低下したが、ソバエキス摂取OLETFラットのインスリン濃度はLETOラットと同レベルの高い値を示した。結果を表1に示す。ソバエキスは糖尿病発症による膵臓ランゲルハンス島β細胞の機能傷害を阻害することで、インスリン分泌低下を抑制することが観察された。 Serum insulin concentrations in OLTF rats fed control diets decreased 5 months after the onset of diabetes, but insulin concentrations in OLETF rats fed buckwheat extract showed the same high level as LETO rats. The results are shown in Table 1. It was observed that buckwheat extract inhibits the decrease in insulin secretion by inhibiting the functional damage of pancreatic islets of Langerhans due to the onset of diabetes.
コントロール食を摂取したOLETFラットの血清および肝臓中性脂肪濃度はLETOラットに対して著しく上昇したが、ソバエキスはOLETFラットの血清および肝臓中性脂肪濃度を効果的に減少させた。結果を表2に示す。 Serum and liver triglyceride levels in OLETF rats fed the control diet were markedly elevated in LETO rats, but buckwheat extract effectively reduced serum and liver triglyceride concentrations in OLETF rats. The results are shown in Table 2.
ソバエキスは、肝臓コレステロール濃度を低下させた。結果を表3に示す。
以上の結果より、ソバエキスは、糖尿病発症を効果的に抑制することが明らかとなった。また、脂質濃度を低下させることで遺伝的に2型糖尿病の素因を有する動物において脂質代謝改善効果を有することも示唆された。 From the above results, it was revealed that buckwheat extract effectively suppresses the onset of diabetes. It was also suggested that reducing lipid concentration has an effect of improving lipid metabolism in animals genetically predisposed to type 2 diabetes.
以下に糖尿病予防用組成物として用いられるソバエキスの配合例を示す。尚、下記配合例は、発明の要旨を限定するものではなく、糖尿病予防用組成物として効果があれば、下記配合例に限定されない。
配合例1:チューインガム
砂糖 53.0重量%
ガムベース 20.0
グルコース 10.0
水飴 16.0
香料 0.5
ソバエキス 0.5
100.0重量%
The following is a blending example of buckwheat extract used as a composition for preventing diabetes. The following formulation examples do not limit the gist of the invention and are not limited to the following formulation examples as long as they are effective as a composition for preventing diabetes.
Formulation Example 1: Chewing gum
53.0% by weight sugar
Gum base 20.0
Glucose 10.0
Minamata 16.0
Fragrance 0.5
Buckwheat extract 0.5
100.0% by weight
配合例2:グミ
還元水飴 40.0重量%
グラニュー糖 20.0
ブドウ糖 20.0
ゼラチン 4.7
水 9.68
ウメ果汁 4.0
ウメフレーバー 0.6
色素 0.02
ソバエキス 1.0
100.0重量%
Formulation Example 2: Gummy
Reduced water tank 40.0% by weight
Granulated sugar 20.0
Glucose 20.0
Gelatin 4.7
Water 9.68
Ume Juice 4.0
Ume Flavor 0.6
Dye 0.02
Buckwheat extract 1.0
100.0% by weight
配合例3:キャンディー
砂糖 50.0重量%
水飴 33.0
水 14.4
有機酸 2.0
香料 0.2
ソバエキス 0.4
100.0重量%
Formulation Example 3: Candy
50.0% by weight sugar
Minamata 33.0
Water 14.4
Organic acid 2.0
Fragrance 0.2
Buckwheat extract 0.4
100.0% by weight
配合例4:ヨーグルト(ハード・ソフト)
牛乳 41.5重量%
脱脂粉乳 5.8
砂糖 8.0
寒天 0.15
ゼラチン 0.1
乳酸菌 0.005
ソバエキス 0.4
香料 微量
水 残余
100.0重量%
Formulation Example 4: Yogurt (hard / soft)
41.5% by weight of milk
Nonfat dry milk 5.8
Sugar 8.0
Agar 0.15
Gelatin 0.1
Lactic acid bacteria 0.005
Buckwheat extract 0.4
Perfume
Water residue
100.0% by weight
配合例5:ソフトカプセル
玄米胚芽油 87.0重量%
乳化剤 12.0
ソバエキス 1.0
100.0重量%
Formulation Example 5: Soft capsule
Brown rice germ oil 87.0% by weight
Emulsifier 12.0
Buckwheat extract 1.0
100.0% by weight
配合例6:コーヒー飲料(液状)
焙煎コーヒー豆 6.0重量%
砂糖 6.0
重曹 0.2
乳化剤 0.15
ソバエキス 1.0
水 残余
100.0重量%
Formulation Example 6: Coffee beverage (liquid)
Roasted coffee beans 6.0% by weight
Sugar 6.0
Baking soda 0.2
Emulsifier 0.15
Buckwheat extract 1.0
Water residue
100.0% by weight
配合例7:コーヒー飲料(粉末)
インスタントコーヒー 90.0重量%
脱脂乳 7.0
ソバエキス 3.0
100.0重量%
Formulation Example 7: Coffee drink (powder)
Instant coffee 90.0% by weight
Skim milk 7.0
Buckwheat extract 3.0
100.0% by weight
配合例8:清涼飲料
果糖ブドウ糖液糖 30.0重量%
乳化剤 0.5
ソバエキス 0.05
香料 適量
精製水 残余
100.0重量%
Formulation Example 8: Soft drink
Fructose glucose liquid sugar 30.0% by weight
Emulsifier 0.5
Buckwheat extract 0.05
Perfume
Purified water residue
100.0% by weight
配合例9:錠剤
乳糖 54.0重量%
結晶セルロース 30.0
澱粉分解物 10.0
グリセリン脂肪酸エステル 5.0
ソバエキス 1.0
100.0重量%
Formulation Example 9: Tablet
Lactose 54.0% by weight
Crystalline cellulose 30.0
Starch degradation product 10.0
Glycerin fatty acid ester 5.0
Buckwheat extract 1.0
100.0% by weight
配合例10:錠菓
砂糖 76.4重量%
グルコース 19.0
ショ糖脂肪酸エステル 0.2
ソバエキス 0.5
精製水 3.9
100.0重量%
Formulation Example 10: Tablet
76.4% by weight of sugar
Glucose 19.0
Sucrose fatty acid ester 0.2
Buckwheat extract 0.5
Purified water 3.9
100.0% by weight
以上、説明したとおり、ソバエキスは、糖尿病予防や改善に効果を有する飲食品や医薬品として十分利用できるものである。 As described above, buckwheat extract can be sufficiently used as a food and drink or a medicine having an effect on diabetes prevention and improvement.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005257166A JP2007070263A (en) | 2005-09-05 | 2005-09-05 | Composition for preventing diabetes mellitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005257166A JP2007070263A (en) | 2005-09-05 | 2005-09-05 | Composition for preventing diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007070263A true JP2007070263A (en) | 2007-03-22 |
Family
ID=37932027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005257166A Pending JP2007070263A (en) | 2005-09-05 | 2005-09-05 | Composition for preventing diabetes mellitus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007070263A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008110551A1 (en) * | 2007-03-12 | 2008-09-18 | Zadec Aps | An anti-diabetic extract of rooibos |
| WO2009049428A1 (en) * | 2007-10-16 | 2009-04-23 | The University Of British Columbia | Alpha-amylase inhibitors: the montbretins and uses thereof |
| ITMI20130171A1 (en) * | 2013-02-07 | 2014-08-08 | Velleja Res Srl | ERGOGENIC-ANABOLIZING COMPOSITIONS BASED ON POLYGONUM FAGOPYRUM |
| GB2586745B (en) * | 2018-03-13 | 2023-04-05 | Nuchido Ltd | Compositions |
-
2005
- 2005-09-05 JP JP2005257166A patent/JP2007070263A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008110551A1 (en) * | 2007-03-12 | 2008-09-18 | Zadec Aps | An anti-diabetic extract of rooibos |
| WO2009049428A1 (en) * | 2007-10-16 | 2009-04-23 | The University Of British Columbia | Alpha-amylase inhibitors: the montbretins and uses thereof |
| US8431541B2 (en) | 2007-10-16 | 2013-04-30 | The University Of British Columbia | Alpha-amylase inhibitors: the montbretins and uses thereof |
| ITMI20130171A1 (en) * | 2013-02-07 | 2014-08-08 | Velleja Res Srl | ERGOGENIC-ANABOLIZING COMPOSITIONS BASED ON POLYGONUM FAGOPYRUM |
| GB2586745B (en) * | 2018-03-13 | 2023-04-05 | Nuchido Ltd | Compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4873824B2 (en) | Carbohydrate absorption inhibitor and method for producing the same | |
| US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
| JP6640392B2 (en) | Obesity control composition | |
| KR20160144791A (en) | Composition for relieving menopausal symptom | |
| CN101766274A (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| CN104666643B (en) | A kind of compound snow chrysanthemum product and its preparation method and application | |
| JP5969529B2 (en) | Anti-inflammatory agent | |
| KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
| JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
| JP5261808B2 (en) | Fat accumulation inhibitor, medicine and method for newly imparting fat accumulation inhibitory action | |
| KR102470155B1 (en) | Oral composition for reducing body weight or body fat comprising Artemisia dracunculus and Taraxacum officinale | |
| JP2007070263A (en) | Composition for preventing diabetes mellitus | |
| JP2008214191A (en) | Agent for suppressing accumulation of lipid in liver | |
| KR20160011846A (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
| US20100040713A1 (en) | Fat absorption inhibitor and food and drink using the same | |
| JP4623999B2 (en) | Aldose reductase activity inhibitor, preventive / therapeutic agent for diabetic complications, and food and drink for the prevention / treatment of diabetic complications | |
| KR101894491B1 (en) | A composition for improving memory or cognitive function comprising a aurantii fructus immaturus supercritical extract as an active ingredient | |
| JP4516958B2 (en) | Anti-diabetic composition | |
| JP2004323439A (en) | Composition for ameliorating blood viscosity | |
| KR20110078237A (en) | Obesity treatment or prevention composition containing loquat extract | |
| KR20170055366A (en) | A composition for preventing or treating obesity comprising taraxacum coreanum root extract | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| JP2007070265A (en) | Composition for improving lipid metabolism | |
| JP2020137496A (en) | Composition containing mulberry leaf processed product |